Assessing the ability of human endothelial cells derived from induced‐pluripotent stem cells to form functional microvasculature in vivo by Bezenah, Jonathan R. et al.
Received: 9 May 2018 | Revised: 22 August 2018 | Accepted: 7 November 2018
DOI: 10.1002/bit.26860
AR T I C L E
Assessing the ability of human endothelial cells derived from
induced‐pluripotent stem cells to form functional
microvasculature in vivo
Jonathan R. Bezenah1 | Ana Y. Rioja2 | Benjamin Juliar2 | Nicole Friend2 |
Andrew J. Putnam1,2
1Department of Chemical Engineering,
University of Michigan, Ann Arbor, Michigan
2Department of Biomedical Engineering,
University of Michigan, Ann Arbor, Michigan
Correspondence
Andrew J. Putnam, PhD, Department of
Biomedical Engineering, University of
Michigan, 2204 Lurie Biomedical Engineering
Building, 1101 Beal Ave, Ann Arbor, 48109
MI.
Email: putnam@umich.edu
Funding information
National Institute of General Medical
Sciences, Grant/Award Number:
T32‐GM008353; National Heart, Lung, and
Blood Institute, Grant/Award Number:
R01‐HL085339
Abstract
Forming functional blood vessel networks is a major clinical challenge in the fields of
tissue engineering and therapeutic angiogenesis. Cell‐based strategies to promote
neovascularization have been widely explored, but cell sourcing remains a significant
limitation. Induced‐pluripotent stem cell‐derived endothelial cells (iPSC‐ECs) are a
promising, potentially autologous, alternative cell source. However, it is unclear
whether iPSC‐ECs form the same robust microvasculature in vivo documented for
other EC sources. In this study, we utilized a well‐established in vivo model, in which
ECs (iPSC‐EC or human umbilical vein endothelial cells [HUVEC]) were coinjected
with normal human lung fibroblasts (NHLFs) and a fibrin matrix into the dorsal
flank of severe combined immunodeficiency mice to assess their ability to form
functional microvasculature. Qualitatively, iPSC‐ECs were capable of vessel forma-
tion and perfusion and demonstrated similar vessel morphologies to HUVECs.
However, quantitatively, iPSC‐ECs exhibited a two‐fold reduction in vessel density
and a three‐fold reduction in the number of perfused vessels compared with HUVECs.
Further analysis revealed the presence of collagen‐IV and α‐smooth muscle actin
were significantly lower around iPSC‐EC/NHLF vasculature than in HUVEC/NHLF
implants, suggesting reduced vessel maturity. Collectively, these results demonstrate
the need for increased iPSC‐EC maturation for clinical translation to be realized.
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1 | INTRODUCTION
Cardiovascular diseases (CVDs) are the leading cause of death
worldwide with total yearly health expenditures and costs associated
with lost productivity exceeding $300 billion and rising (Mozaffarian
et al., 2015). Many of these patients suffer from atherosclerosis,
characterized by hardening of the vessels and typically caused by
buildup of a cholesterol‐rich plaque in an artery (Taleb, 2016).
Atherosclerotic lesions can cause ischemia, a reduction or obstruction
of oxygenated blood supply to tissues, which can lead to tissue damage
and eventually necrosis (Davies, 2012). With the number of deaths and
costs attributed to CVD expected to rise over the next decade, there is
an urgent clinical need for new approaches to revascularize ischemic
tissues to prevent necrosis, amputations, and ultimately death (Roger
et al., 2011; Tarride et al., 2009).
A variety of therapeutic strategies have been investigated in
recent years to direct angiogenesis. Growth factor delivery has
been extensively studied to promote endothelial cell (EC) recruit-
ment and eventually increase vessel formation (Kannan et al., 2005;
Yancopoulos et al., 2000). However, growth factor based therapies
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face various challenges, including protein instability, the need for
precision delivery, and rapid degradation (Sun et al., 2010).
Alternative tissue engineering approaches have attempted to
revascularize ischemic tissues using cell transplantation (Rubina
et al., 2009; Zhang et al., 2008). Codelivering ECs with stromal cells
embedded in a hydrogel biomaterial promotes the formation of
stable, mature microvasculature (Au, Tam, Fukumura, Jain, 2008;
Koike et al., 2004; Melero‐Martin et al., 2008; Rouwkema, Rivron,
van Blitterswijk, 2008). However, cell‐based approaches have their
own set of limitations, including potential immunorejection by the
host. Perhaps, the most critical challenge that must be overcome is
the need for a plentiful cell source to supply the billions of cells
required for clinical translation (Ikada, 2006; Saigawa et al., 2004).
A great deal of enthusiasm emerged with the creation of induced‐
pluripotent stem cells (iPSCs). Using four transcription factors (Oct4,
Sox2, Klf4, and cMyc [OSKM]), adult somatic cells can be
reprogramed into a pluripotent stem cell‐like state (Takahashi &
Yamanaka, 2006). Because iPSCs are dedifferentiated from a
potentially autologous somatic cell type, using them as a cell source
not only minimizes ethical concerns associated with other pluripotent
cell sources but may also potentially bypass immunological concerns
in clinical applications (Yee, 2010). Even if derived from allogeneic
sources, iPSCs and their theoretical ability to proliferate indefinitely
could ultimately overcome biomanufacturing hurdles by providing a
large reservoir of cells necessary for human translation (Wong,
Sayed, Cooke, 2013).
Endothelial‐like cells, characterized by their expression of EC
markers, can be differentiated from iPSCs (Ikuno et al., 2017; Yoder,
2015). Their functional abilities to form vessel‐like networks both in
vitro and in vivo have also been described (Adams et al., 2013;
Margariti et al., 2012; Rufaihah et al., 2013). However, because the
potential of these cells has been lauded without appropriate
benchmarking against other EC sources, we recently investigated
the vasculogenic potential of iPSC‐ECs in a well‐established three‐
dimensional cell culture model of sprouting angiogenesis (Bezenah,
Kong, Putnam, 2018). The quantity, quality, and function of the vessel‐
like networks formed by these cells were compared with human
umbilical vein endothelial cells (HUVECs), another EC source with a
proven capability of capillary morphogenesis. Our worked revealed
sprouting by iPSC‐ECs was significantly reduced (vs. HUVECs) and
identified differences in MMP‐9 expression as a possible mechanistic
explanation (Bezenah et al., 2018). Despite highlighting these
differences, the question remains if this attenuation is only an in vitro
phenomenon.
In this present study, we compared the in vivo vascularization
potential of iPSC‐ECs head‐to‐head with HUVECs. ECs (either iPSC‐ECs
or HUVECs) and normal human lung fibroblasts (NHLFs) were
coinjected subcutaneously within a fibrin matrix into the dorsal flank
of severe combined immunodeficiency (SCID) mice. Vessel formation
was characterized by quantifying vessel density, vessel perfusion, and
markers of vessel maturity. Our findings demonstrate iPSC‐ECs are
unable to form vessels of equal quality and quantity compared with an
established EC source.
2 | MATERIALS AND METHODS
2.1 | Cell culture
HUVECs were harvested from fresh umbilical cords following a
previously established protocol (Ghajar et al., 2006). HUVECs were
plated with endothelial growth media (EGM‐2; Lonza, Walkersville, MD)
in tissue culture flasks and cultured at 37 °C and 5% CO2. Media were
changed every 48 hr and cells were used at passage 3. NHLFs (Lonza)
were cultured at 37 °C and 5% CO2 in Dulbecco’s modified Eagle’s
media (DMEM; Life Technologies, Grand Island, NY) with 10% fetal
bovine serum (FBS). Culture media were replaced every 48 hr and cells
from passage 6 to 10 were used in experiments. iCell ECs (Cellular
Dynamics International, Madison, WI), referred to as iPSC‐ECs, were
cultured at 37 °C and 5% CO2 in Vasculife VEGF endothelial medium
(Lifeline Cell Technology, Fredrick, MD) supplemented with iCell
Endothelial Cell Medium Supplement (Cellular Dynamics International),
per the manufacturer’s instructions. iPSC‐EC’s tissue culture flasks were
coated with 35 µg/ml fibronectin (Invitrogen, Carlsbad, CA) for 1 hr at
room temperature before plating the cells. Culture media were replaced
every 48 hr and cells from passage 3 were used in experiments.
2.2 | Sample preparation for subcutaneous
injection
A 2.5mg/ml bovine fibrinogen (92% clottable; Sigma‐Aldrich,
St. Louis, MO) solution was prepared by dissolving the protein in an
appropriate amount of serum‐free EGM‐2 and placed in a water bath
at 37 °C. The solution was sterile filtered through a 0.22 µm‐syringe
filter (Millipore, Billerica, MA). Cells were cultured in T‐75 flasks to
80% confluency and rinsed with phosphate‐buffered saline (PBS)
before being harvested via 0.25% trypsin incubation for 5min at 37 °C
and 5% CO2. Trypsin was neutralized using DMEM supplemented with
10% FBS. The cellular suspension was centrifuged (200g for 5min) and
supernatant was aspirated immediately. Cells were resuspended at a
1:1 ratio of ECs:NHLFs in the previously prepared fibrinogen solution
at a final concentration of four million cells/ml, totaling two million
cells per injection (500 μl). Immediately before injection, 5% FBS and
12 μl of thrombin solution (50U/ml; Sigma‐Aldrich) were added to the
500 μl of fibrinogen‐cell solution. A cellular controls containing
fibrinogen, FBS, and thrombin were also prepared.
2.3 | Subcutaneous injections
All animal procedures were performed in accordance with the
National Institutes of Health (NIH) guidelines for laboratory animal
usage and approved by the University of Michigan’s, Institutional
Animal Care and Use Committee. Male CB17/SCID mice (6–8 weeks
old; Taconic Labs, Hudson, NY) were used for all experiments. The
mice were allowed to acclimate for ≥72 hr after arrival. Before
surgery, mice were weighed and marked with permanent marker to
identify experimental conditions. The mice were then anesthetized in
an induction chamber with 5% isoflurane at 1 L/min O2 (Cryogenic
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Gases, Detroit, MI) using a V‐1 Tabletop isoflurane vaporizer system
equipped with an Active Scavenging Unit (VetEquipt, Livermore, CA).
Once mice were fully anesthetized, they were moved to a surgery
bench and fitted with an active scavenging nose cone. The isoflurane
level was reduced to 1–1.5%, depending on weight, during surgery to
maintain anesthesia. Ophthalmic ointment (Puralube® 499 vet
ointment; Dechra, Overland Park, KS) was added to the eyes of each
mouse. An analgesic, carprofen (5mg/kg), was then administered to
each animal via intraperitoneal injection. The dorsal flanks of each
mouse were shaved and depilatory agent (Nair; Thermo Fisher
Scientific, Pittsburg, PA) was applied to remove any remaining hair.
Ethanol and betadine (Thermo Fisher Scientific, Fremont, CA) were
applied alternating three times each to sterilize the injection site. The
injection samples were then prepared, as described above. Each
solution was rapidly mixed and drawn into a 1mL‐syringe fitted with a
BD PrecisionGlide™ 20G‐needle (Becton Dickson, Franklin Lakes, NJ).
The mixture (500 μl) was immediately injected subcutaneously on the
dorsal flank of the mouse, with two implants per animal, one on each
flank. The needle was left in the injection site for 1min to allow for the
solution to polymerize. Mice were then placed in a recovery cage to
recover from the anesthesia, and then returned to their normal
housing environment. Mice were monitored daily postsurgery. A total
of 18 mice (4 implants/cell condition x 3 time points x 3 cell conditions
x 2 implants/mouse) were used for this study. Bilateral implants were
injected per animal, one on each flank in a randomized fashion.
2.4 | Implant retrieval postprocessing
Animals were euthanized on Days 4, 7, or 14 after implants were
injected. The implants were surgically excised from each mouse via
gross dissection and placed immediately in Z‐fix (Thermo Fisher
Scientific). After a 24 hr‐fixation, implants were washed thrice in PBS
and stored in 70% ethanol at 4°C until further processing. Excess
tissue was then removed from the implant using forceps and scissors,
and samples were placed in embedding cassettes (UNISETTE cassette
with lid; Simport, Beloeli, QC, Canada), dehydrated, and embedded in
paraffin using a KD‐BMII tissue embedding center (IHCWorld, Ellicott
City, MD). For further analysis, embedded samples were sectioned
(6‐μm thick sections) with a Thermo Fisher Scientific HM 325 rotary
microtome and placed on glass slides with six sections per slide.
2.5 | Hematoxylin and eosin staining
Paraffin sections on glass slides were dewaxed in xylene baths twice
for 5min. Slides were then washed twice in each decreasing ethanol
concentration (100, 95, and 70%) bath for 3min. Lastly, slides were
rehydrated in deionized water for 3min before staining with Mayer’s
hematoxylin (Electron Microscopy Sciences, Hatfield, PA) for 15min.
Slides were then rinsed in tap water for 15min and briefly placed in
95% ethanol for 30 s. Following, slides were immersed in Eosin Y
(Sigma‐Aldrich) for 1min and dehydrated twice in each increasing
ethanol concentration (95 and 100%) bath for 1min. Samples were
cleared by washing in xylene baths twice for 3 min. Toluene mounting
solution (Permount; Thermo Fisher Scientific) was added to cover-
slips before placing on top of each slide. Slides were left to dry before
imaging.
2.6 | Immunohistochemical staining
Implant region locations were first approximated with the aforemen-
tioned hematoxylin and eosin (H&E) staining. Serial sections were
deparaffinized and rehydrated following the same protocol described
for hematoxylin and eosin staining. Slides were then steamed in a
vegetable steamer (95–99°C) for 35min in an antigen retrieval solution
(Dako, Carpinteria, CA) and equilibrated to room temperature for 30min.
Slides were washed thrice in 0.1% Tween 20 Tris‐buffered saline (TBS‐T)
for 2min/wash, whereas changing the baths for every wash. Excess
moisture was removed from each slide and the area around the tissue
was marked with an ImmEdge pen (Vector Laboratories, Inc, Burlingame,
CA). The Dako EnVision System‐HRP (DAB) kit (Dako) was utilized to
detect labeled antigens in the sections. First, peroxidase blocking solution
was added to each tissue section for 5min. Slides were subsequently
washed thrice in 0.1% Tween 20 TBS‐T for 2min/wash (changing baths
between washes). Mouse anti‐human CD31 primary antibody (1:50;
Dako), mouse anti‐human smooth muscle actin antibody (1A4 (asm‐1));
(1:200; Thermo Fisher Scientific), or mouse anti‐human collagen‐IV
(COL‐IV) monoclonal antibody (COL‐94; 1:500; Thermo Fisher Scientific)
were diluted in TBS‐T and added to each tissue sample. Primary
antibodies were incubated for 16 hr at 4°C for both CD31 and COL‐IV
and 2hr at room temperature for α‐smooth muscle actin (α‐SMA). After
incubations, samples were rinsed thrice with TBS‐T at 2min/wash. The
horseradish peroxidase‐labeled polymer solution was then added to each
sample and incubated for 30min at room temperature. Samples were
washed once again as described above. DAB+ substrate‐chromogen
buffer solution was then added to each tissue section for 5min, and
immediately rinsed in deionized water for 30 s. Samples were counter-
stained with hematoxylin for 15min, followed by a 15min wash in tap
water. Slides were then washed, as described for H&E staining, with 95%
ethanol, 100% ethanol, and xylene to dehydrate the samples. Lastly,
toluene mounting solution was added to each slide before covering the
samples with coverslips. Slides were left to dry before imaging.
2.7 | Vessel quantification
After staining, slides were imaged using an Olympus IX81 microscope
with a DP2‐Twain color camera (Olympus America, Center Valley,
PA) and the CellSens Imagining Software (Olympus) for visualizing
stained slides. Brightfield images were taken using x4 and x20
objectives for each of the various positively‐stained marker region of
the sections. A x40 objective was used to image individual vessels.
Positively‐stained sections from three separate implants for each
condition, with five random x20 images per section, were then
quantified to determine average vessel density on a per mm2 basis
for each of the indicated expression markers. Structures were
considered a blood vessel if they exhibited a hollow lumen
surrounded by a complete brown rim of positive stain. Quantification
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of vessels derived from the transplanted human cells was conducted
by two independent evaluators via a one‐side blinded study for
hCD31. Lumen diameter was also quantified by each evaluator using
Image J (National Institutes of Health, Bethesda, MD). Quantification
of vessels expressing α‐SMA and COL‐IV proceeded via the same
methods described above, but were unblinded. Acellular fibrin
controls were not analyzed or shown because they did not contain
any human EC‐derived vessels.
2.8 | Statistical analysis
Statistical analyses were performed using the StatPlus (AnalystSoft
Inc, Walnut, CA). One‐way analysis of variance with a Bonferroni
posttest was used to assess statistical significance between datasets.
Data are reported as mean ± standard error of mean (SEM). Statistical
significance was assumed when p < 0.05.
3 | RESULTS
3.1 | iPSC‐EC/NHLF fibrin implants are capable of
vascular morphogenesis in vivo
In this study, HUVECs and iPSC‐derived ECs were characterized for
their abilities to form microvasculature when coinjected with NHLFs
in a three‐dimensional fibrin matrix into subcutaneous pockets in
vivo. H&E staining of tissue sections from these implants demon-
strated the presence of vessel structures across all time points
(Figure 1). Despite the evidence of vessel formation and the presence
of lumens for both EC types at each time point, the vessels formed by
Day 4 were comparatively smaller relative to the later time points
(Figure 1a,d). Vessels identified in Day 4 sections also showed
minimal evidence of inosculation with host microvasculature due to
relative absence of host erythrocytes observed within the lumens or
in the surrounding matrix. However, by Days 7 and 14, constructs
exhibited larger vessel morphologies and host erythrocytes were
increasingly apparent throughout the implant region (Figure 1b,c,e,
and f). Sections from both Days 7 and 14 show evidence of vessel
perfusion. The erythrocytes were largely contained within the
lumens of the neovessels formed by both EC types (as opposed to
leaking into the interstitial tissue space) at the Day 14 time point.
Collectively, these results suggest the iPSC‐ECs and HUVECs form
functional microvasculature with similar qualities in vivo.
3.2 | iPSC‐ECs produce vessels with comparable
morphologies and similar diameters
To validate the observations from the H&E‐stained sections and
confirm the human origins of the neovasculature, human ECs were
identified in explanted tissue constructs via immunohistochemical
staining of human CD31 (Figure 2a–f). Both EC types demonstrated
hollow lumens surrounded by a brown rim of positive staining at each
time point, confirming successful vessel formation by the implanted
human cells as suggested by the H&E stain. Vessels also demonstrated
morphological similarities with both cell conditions. Furthermore,
Day 4 Day 14Day 7
(a) (b) (c)
(f)(e)(d)
200 μm 
200 μm 200 μm 
200 μm 200 μm 
200 μm 
HUVEC
iPSC-EC
F IGURE 1 Histological staining illustrates in vivo vessel formation and similar phenotypes across cell types representative images of
subcutaneous implants stained with hematoxylin and eosin. Implants were formed by coinjecting HUVECs (a–c) or iPSC‐ECs (c–f) with NHLFs in
2.5mg/ml fibrin. Implants were harvested at Days 4 (a,d), 7 (b,e), and 14 (c,f). Insets are images from a x40 objective lens, taken from the region
indicated with black‐dashed lines, to more clearly show vessel morphologies and the presence of host erythrocytes. The white‐dashed lines are to
indicate the boundary between the implant and mouse tissue, whereas arrows point to the implant region (Scale bar = 200 μm). HUVEC: human
umbilical vein endothelial cell; iPSC‐EC: induced‐pluripotent stem cell‐derived endothelial cell [Color figure can be viewed at wileyonlinelibrary.com]
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vessel lumens demonstrated similarities in size. Quantification of the
inner lumen diameter supported these qualitative observations (Figure
2g–i) demonstrating no significant differences between the HUVEC
and iPSC‐EC condition across all time points (12.03 ± 1.45,
16.33 ± 1.19 , and 14.04 ± 1.15 µm for iPSC‐ECs vs. 12.30 ± 0.38,
17.58 ± 1.32 , and 15.59 ± 2.01 µm for HUVECs on Dayds 4, 7, and
14, respectively). Despite slightly smaller lumens at the Day 4 time
point, there were also no significant differences between time points
for each of the cell conditions (Figure 2j,k).
3.3 | iPSC‐ECs exhibit deficiencies in vessel
formation compared to HUVECs in vivo
Our previous study demonstrated that iPSC‐ECs are quantitatively
deficient in vascular network formation in vitro compared with
HUVECs (Bezenah et al., 2018). To investigate the extent of network
formation in vivo, sections from subcutaneous implants were stained
with an EC marker, hCD31, and the number of vessels throughout a
given area were quantified. Vessels with clearly identifiable lumens
surrounded by a positive hCD31 brown rim were counted. Repre-
sentative images of average vessel density for both HUVECs and iPSC‐
ECs at varying time points are shown in Figure 3a–f. Quantification of
the vessel density (Figure 3g–i) revealed significant differences in the
average number of vessels/mm2 at Days 4 and 7 (42.27 ± 4.82 and
86.43 ± 21.86 µm for HUVECs vs. 25.48 ± 4.41 and 35.58 ± 7.62 µm
for iPSC‐ECs on Days 4 and 7, respectively). However, at later time
points, Day 14, there were no significant differences between the
iPSC‐EC and HUVEC condition with relatively equal average number
of vessels/mm2 (37.61 ± 13.61 µm for HUVECs vs. 36.46 ± 3.76 µm for
iPSC‐ECs on Day 14, respectively). Vessel density peaked for the
Day 4 Day 14Day 7
HUVEC
iPSC-EC
(a) (b) (c)
(f)(e)(d)
(h)(g) (i)
200 μm 
200 μm 
200 μm 
200 μm 200 μm 
200 μm 
F IGURE 2 Both iPSC‐ECs and HUVECs express comparable vessel morphologies with similar vessel diameters representative images of
human CD31‐stained HUVECs (a–c) or iPSC‐ECs (d–f) subcutaneous implants at various time points. All images were counterstained with
hematoxylin. Implants were harvested at Days 4 (a,d), 7 (b,e), and 14 (c,f). Insets are images from a x40 objective lens and dashed lines are
present to more clearly show similarities between vessel diameters (Scale bar = 200 μm). Vessel diameters, both with or without erythrocytes,
were measured and quantified over a total of 5 random images per selected section across three separate animals. Quantifications were
single‐blinded and averaged at the given time points (g–i). Error bars indicate ±SEM. HUVEC: human umbilical vein endothelial cell; iPSC‐EC:
induced‐pluripotent stem cell‐derived endothelial cell; SEM: standard error of mean [Color figure can be viewed at wileyonlinelibrary.com]
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HUVECs at Day 7 and regressed by Day 14, whereas iPSC‐EC vessel
density increased over time.
3.4 | iPSC‐ECs vessels exhibit less perfusion
compared to HUVECs
Once the baseline density of vessels formed by the implanted cell
types was established, any differences in functionality of these newly
formed vessels were examined. To evaluate functional anastomoses
with the host vasculature, the numbers of vessel lumens perfused with
erythrocytes were quantified. Once again, vessels were quantified only
if lumens surrounded by a positive hCD31 brown rim were clearly
present and erythrocytes were clearly visible within the lumen.
Representative images of average number of perfused vessels for both
HUVECs and iPSC‐ECs at varying time points are shown (Figure 4a–f).
Erythrocytes can clearly be seen in higher magnification inserts.
Quantification of these vessels (Figure 4g–i) demonstrated no
significant differences in the average number of perfused vessels/
mm2 at Day 4 (4.54 ± 1.89 µm for iPSC‐ECs vs. 2.39 ± 2.25 µm for
HUVECs). However, at Day 7, iPSC‐ECs exhibited a statistical
significant reduction in perfused vessel density compared with
HUVECs (22.83 ± 4.06 µm vs. 72.81 ± 21.72 , respectively). No sig-
nificant differences were seen once again by Day 14. Whereas
iPSC‐EC vessel perfusion increased over time, HUVEC vessel
perfusion peaked at Day 7, but decreased to similar levels as iPSC‐
ECs by Day 14.
Day 4 Day 14Day 7
(a) (b) (c)
(f)(e)(d)
200 μm 
200 μm 200 μm 
200 μm 
200 μm 
200 μm 
HUVEC
iPSC-EC
(g) (h) (i)
F IGURE 3 iPSC‐ECs exhibit deficiencies in vessel lumen formation compared with HUVECs representative images of subcutaneous implants
immunohistochemically stained for human CD31 demonstrate the formation of vessel structures with lumens by HUVECs (a–c) or iPSC‐ECs
(d–f) in subcutaneous implants at various time points. All images were counterstained with hematoxylin. Implants were harvested at Days 4
(a,d), 7 (b,e), and 14 (c,f). Insets are images from a x40 objective lens to more clearly show vessel lumens (Scale bar = 200 μm). A total of five
random images per selected section across three separate animals were quantified for +hCD31 vessels with lumens. Quantifications were
single‐blinded, averaged, and normalized to the respective, +hCD31 implant area of each EC type at the given time points (g–i). *p < 0.05 and
comparing the indicated condition to the HUVEC condition. Error bars indicate ±SEM. HUVEC: human umbilical vein endothelial cell; iPSC‐EC:
induced‐pluripotent stem cell‐derived endothelial cell; SEM: standard error of mean [Color figure can be viewed at wileyonlinelibrary.com]
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3.5 | iPSC‐ECs express differences in vessel
maturity in vivo compared to HUVECs
Despite the iPSC‐ECs’ ability to form vessel‐like structures in vivo,
the quality of the structures was also examined to determine if they
exhibit qualitative characteristics of mature capillaries in vivo. To
assess vessel development and maturity, sections serial to the
positively‐stained hCD31 samples in the previous experiments were
immunohistochemical (IHC) stained and quantified for various
maturity markers to identify pericytic association of the coimplanted
NHLFs and basement membrane deposition by the ECs. Vessels were
quantified only if they were previously identified as human origin
through hCD31 staining in former tissue section, and erythrocytes
were present in the lumen. Representative images reveal the
presence of α‐SMA, across all time points for both iPSC‐ECs and
HUVECs, suggesting recruitment and a pericyte‐like phenotype of
the coimplanted NHLFs (Figure 5a–d). Pericytes stabilize nascent
endothelium and are characterized by physical association with ECs
as well as expression of molecular markers such as α‐SMA (Skalli
et al., 1989). Quantification of the vessel density indicated significant
differences in α‐SMA at both time points between iPSC‐ECs and
HUVECs (Figure 5e,f). The number of vessels surrounded by α‐SMA
also increased from Days 7 to 14 for both cell conditions.
We next characterized basement membrane deposition with human
collagen‐IV immunohistochemical staining. COL‐IV is a prominent
Day 4 Day 14Day 7
(a) (b) (c)
(f)(e)(d)
200 μm 
200 μm 200 μm 
200 μm 200 μm 
200 μm 
HUVEC
iPSC-EC
(g) (h) (i)
F IGURE 4 iPSC‐ECs vessels are less perfused compared with those formed by HUVECs representative images of subcutaneous implants
immunohistochemically stained for human CD31 demonstrate the formation of vessel structures with perfused lumens (identified by the
presence of erythrocytes) by HUVECs (a–c) or iPSC‐ECs (d–f) in subcutaneous implants at various time points. All images were counterstained
with hematoxylin. Implants were harvested at Days 4 (a,d), 7 (b,e), and 14 (c,f). Insets are images from a x40 objective lens to more clearly show
vessel lumens (Scale bar = 200 μm). A total of five random images per selected section across three separate animals were quantified for
+hCD31 vessels with erythrocytes in the lumens. Quantifications were single‐blinded, averaged, and normalized to the respective +hCD31
implant area of each EC type at the given time points (g–i). *p < 0.05 and comparing the indicated condition to the HUVEC condition. Error bars
indicate ±SEM. HUVEC: human umbilical vein endothelial cell; iPSC‐EC: induced‐pluripotent stem cell‐derived endothelial cell; SEM: standard
error of mean [Color figure can be viewed at wileyonlinelibrary.com]
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component in basement membranes (Li and Thompson, 2003).
Representative images reveal the presence of COL‐IV across all time
points for both iPSC‐ECs and HUVECs (Figure 6a–d). Quantification of
the vessel density indicated significant differences in COL‐IV at both
time points between iPSC‐ECs and HUVECs (Figure 6e,f). However,
there was little change in expression between the two time points for
both cell conditions. Collectively, this data demonstrates that are iPSC‐
ECs vessels lack maturity in comparison with HUVEC.
4 | DISCUSSION
Due to a critical need for a more sustainable and abundant clinically
relevant cell source, the vascularization potential of iPSC‐ECs is of
increasing interest. In previous studies, using a three‐dimensional
fibrin‐based in vitro model, we demonstrated that iPSC‐ECs’ capillary
morphogenesis was significantly attenuated, with reduced MMP‐9
expression as one possible candidate for such phenomena (Bezenah
et al., 2018). Whereas prior studies have shown that iPSC‐ECs are
capable of forming vessel‐like structures in vivo within supporting
Matrigel matrices (Adams et al., 2013; Margariti et al., 2012), there is
little evidence comparing their in vivo potential with more widely
utilized EC sources. Therefore, this study explored the ability of iPSC‐
ECs to create functional vessel‐like structures in a fibrin‐based
subcutaneous implant and compared the quantity and quality of such
vessels formed against HUVECs. When codelivered with stromal
fibroblasts (NHLFs), iPSC‐ECs formed functional microvessels that
inosculated with host vasculature; however, the resultant vasculature
was of significantly lower density quantitatively and less mature
qualitatively when compared to that formed by HUVECs.
Fibrin was selected as the material for implantation because it is a
naturally occurring biopolymer that promotes wound healing and
Day 7 Day 14
(a)
(c) (d)
(b)
200 μm
200 μm
200 μm
200 μm
HUVEC
iPSC-EC
(e) (f)
F IGURE 5 α‐SMA staining of vessels formed by iPSC‐ECs show differences in vessel maturity compared with those formed by HUVECs
representative images of α‐SMA‐stained histological sections from subcutaneous implants formed from either HUVECs (a,b) or iPSC‐ECs (c,d) at
various time points. All images were counterstained with hematoxylin. Implants were harvested at Days 7 (a,c) and 14 (b,d). Insets are images from
a x40 objective lens to more clearly show positive α‐SMA staining around vessel lumens (Scale bar = 200 μm). Vessel lumens surrounded by α‐SMA
were quantified over a total of five random images per selected section across three separate animals. Quantifications were averaged and
normalized to the respective +human α‐SMA implant area of each EC type at the given time points (e,f). *p < 0.05 and comparing the indicated
condition to the HUVEC condition. Error bars indicate ±SEM. HUVEC: human umbilical vein endothelial cell; iPSC‐EC: induced‐pluripotent stem
cell‐derived endothelial cell; SEM: standard error of mean; α‐SMA: α‐smooth muscle actin [Color figure can be viewed at wileyonlinelibrary.com]
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neovascularization (Christman et al., 2004) and is Food and Drug
Administration cleared for some uses in humans (Ceccarelli & Putnam,
2014). In addition, fibrin was selected for these studies due to its track
record of supporting neovascularization in vivo (Blache & Ehrbar,
2018; Ceccarelli & Putnam, 2014; Christman et al., 2004). and to
match our prior in vitro study in which we evaluated the potential of
iPSC‐ECs relative to HUVECs (Bezenah et al., 2018). NHLFs were
chosen due to their ability to aid in the formation of microvascular
networks, adopt a mural cell‐like localization around the vessel‐like
structures, and express a subset of pericyte markers as previously
reported (Ghajar et al., 2006; Ghajar et al., 2008; Grainger, Carrion,
Ceccarelli, Putnam, 2013; Peterson et al., 2014). We selected a 1:1
ratio of ECs to stromal cells based on previous studies from our group
and others (Grainger et al., 2013; Melero‐Martin et al., 2008; Rao
et al., 2012). HUVECs are a robust EC source and were selected for
their proven capability of capillary morphogenesis not only in
the model used for this study, but in other in vivo models as well
(D.Y. Chen et al., 2004; Grainger et al., 2013; Kniazeva, Kachgal,
Putnam, 2011). The animal model used here has been widely explored
in the literature to approximate wound healing and test the ability of
transplanted human cells to form vasculature (Allen, Melero‐Martin,
Bischoff, 2011; X. Chen et al., 2010; Melero‐Martin et al., 2008;
Traktuev et al., 2009) This model also avoids potential immunorejec-
tion of the human cells injected into SCID mice.
H&E staining of the retrieved implants suggested some simila-
rities, in terms of morphology and phenotype, across the different EC
conditions. Both iPSC‐ECs and HUVECs formed vessels with similar
lumen diameters and shapes across all time points. Capillary
diameters are typically around 4 µm (Potter & Groom, 1983).
Whereas our results reveal three‐ to four‐fold larger lumen
Day 7 Day 14
(a)
(c) (d)
(b)
200 μm
200 μm
200 μm
200 μm
HUVEC
iPSC-EC
(e) (f)
F IGURE 6 COL‐IV staining of vessels formed by iPSC‐ECs show differences in vessel maturity compared with those formed by HUVECs
representative images of COL‐IV‐stained histological sections from subcutaneous implants formed from either HUVECs (a,b) or iPSC‐ECs
(c,d) at various time points. All images were counterstained with hematoxylin. Implants were harvested at Days 7 (a,c) and 14 (b,d). Insets are
images from a x40 objective lens to more clearly show COL‐IV surrounding vessel lumens (Scale bar = 200 μm). Vessel lumens surrounded by
COL‐IV were quantified over a total of five random images per selected section across three separate animals. Quantifications were averaged
and normalized to the respective +human COL‐IV implant area of each EC type at the given time points (e,f). *p < 0.05 and comparing the
indicated condition to the HUVEC condition. Error bars indicate ±SEM. HUVEC: human umbilical vein endothelial cell; iPSC‐EC: induced‐
pluripotent stem cell‐derived endothelial cell; SEM: standard error of mean [Color figure can be viewed at wileyonlinelibrary.com]
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diameters, capillary diameters can range much larger depending on
the tissue (Wiedeman, 1963). The larger diameters could also
indicate less mature vessel formation. As the neovasculature
matures, ECs form tightly regulated junctions to each other (Xu &
Cleaver, 2011). The ECs in our study may not yet have formed these
tight boundaries leading to increased extracellular space between
each cell and therefore causing the larger than expected diameters.
The vessels formed also exhibit a slightly irregular morphology, and
lacked a definitive circumscribed geometry. Vessel cross‐sections
typically yield lumens with an orbicular shape (Gao & Drew, 2014).
Whereas once again, this could be indicative of less mature
vasculature that has yet to form a more robust geometry, these
results are consistent with our previous studies (Grainger et al.,
2013). Vessels formed by both types of ECs contained few, if any,
erythrocytes at Day 4 within their lumens. Their presence at later
time points suggests inosculation with the host vasculature occurred
between Days 4 and 7. Qualitatively, extravascular erythrocytes
decreased by Day 14, similar to a previous study (Grainger et al.,
2013), suggesting stabilization and maturation of vessels. However,
free erythrocytes still remained in the interstitial space of constructs
containing iPSC‐ECs, further supporting the aforementioned lack of
vessel maturity.
Despite morphologic and phenotypic similarities in vessels formed
from both EC types, IHC staining for hCD31 demonstrated quantitative
differences in the vasculogenic abilities of iPSC‐ECs. This may be due
to reduced abilities of iPSC‐ECs (relative to HUVECs) to proteolytically
degrade the fibrin matrix, as they exhibit reduced expression of
MMP‐9 (Bezenah et al., 2018). However, while vessel density was
significantly reduced at Days 4 and 7, there were no significant
differences between iPSC‐ECs and HUVECs at later time points.
Quantification of vessels containing erythrocytes further revealed
vasculature formed by iPSC‐ECs was less perfused. Early time points
showed no difference between the two cell conditions, but the relatively
low density of perfused vessels indicates the neovascualture formed did
not sufficiently inosculate with the host’s vasculature at this time. The
large increase in vessel diameter by Day 7 suggests inosculation
sometime between Days 4 and 7. We attributed the observed
significant differences in vessel density (both total and perfused vessels)
to the reduced abilities of iPSC‐ECs to undergo capillary morphogenesis.
By Day 14, densities of perfused vessels in implants containing either
HUVECs or iPSC‐ECs were similar due to significant reduction in vessel
density for the HUVEC group. This regression in the HUVEC group is
consistent with a previous study from our group (Grainger et al., 2013).
Vessels undergo selective branch regression and pruning during the
normal process of wound healing angiogenesis, changing network
architecture over time as tissue metabolic demands change (Korn &
Augustin, 2015). This could be a result of increased tissue oxygenation
by the HUVEC group at earlier time points, causing a downregulation of
VEGF expression, a key signal involved in EC proliferation and invasion
during vessel formation, and EC apoptosis in the newly established
vessels (Simonavicius et al., 2012).
In addition to the observed differences in vessel quantity, vessels
formed by the iPSC‐ECs showed lower levels of COL‐IV and α‐SMA
staining, which may be indicative of a reduced maturity. COL‐IV is a
prominent component of the basement membrane of mature
capillaries (Li, 2003), and thus the presence of this component is
indicative of ECs’ ability to form mature capillary networks. In
addition, smooth muscle α‐actin is commonly used as a pericyte
marker (Skalli et al., 1989), although not a very selective one as it also
stains myofibroblasts (Hinz, 2007). Pericytes stabilize nascent
vasculature and their presence suggests mature capillary networks
(Ghajar et al., 2010; Skalli et al., 1989). As revealed by positive α‐SMA
staining, the coimplanted NHLFs associated with the vessels formed
in a pericyte‐like manner. However, whether these NHLFs are
capable of becoming bonafide pericytes in either EC condition is
difficult to prove given the limited availability of bonafide pericyte
markers (Bexell et al., 2009; Shi & Gronthos, 2003). Although still
significantly different compared with the HUVECs, iPSC‐ECs
demonstrated an increase in α‐SMA+ staining at Day 14, perhaps
indicating more recruitment of the NHLFs over time. Collectively,
these data suggest iPSC‐ECs are capable of recruiting and signaling
stromal cells to differentiate into pericytes and depositing the
components necessary for a basement membrane in vivo, but to a
lesser degree than HUVECs.
Despite these differences in comparison to HUVECs, the iPSC‐ECs
performed better in vivo than expected relative to our previous in vitro
findings (Bezenah et al., 2018). This perhaps suggests the in vivo
microenvironment is able to induce the iPSC‐ECs to attain a more
mature phenotype. As the iPSCs from which the iPSC‐ECs were
differentiated were themselves generated from fibroblasts via an
artificial reprogramming process, the iPSC‐ECs have never been exposed
to physiologic conditions, including blood flow. Shear stresses play a
critical role in vascular development and EC phenotype (Rundek & Della‐
Morte, 2015), and one avenue for future studies would be to explore the
ability to induce maturation of the iPSC‐ECs through exposure to fluid
flow. In addition, while this experiment chose to use NHLFs as the
stromal cells for coinjection, different stromal cells may better support
iPSC‐ECs vessel formation. Recent research has demonstrated differ-
ences in vascular morphogenesis of iPSC‐ECs in vitro when cocultured
with stromal cells of varying identities (Halaidych et al., 2018).
Coinjecting different stromal cells may aid in the maturation of the
iPSC‐ECs and as a result, increase the number of vessels formed.
Furthermore, while the subcutaneous implant model used here is
relatively simple and effectively demonstrated differences in vessel
formation, evaluating iPSC‐ECs in more advanced in vivo models is
critical to aid clinical translation. For example, a window‐chamber model
has enabled real‐time visualization of vessel formation and anastomosis
(G. Cheng et al., 2011) and may be useful to understand the abilities of
iPSC‐ECs to inosculate with host vessels. Similarly, hind limb ischemia
models, where the lack of oxygen and nutrients may be more challenging
(or more stimulatory) for vessel formation, have already been used to
demonstrate the ability of iPSC‐ECs to rescue ischemic tissue in a
situation that better replicates the clinical target (Rufaihah et al., 2011).
Our data here underscore the importance of comparing the efficacy of
iPSC‐ECs head‐to‐head with HUVECs (and other sources of ECs) in
these more advanced models as well.
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In summary, this study assessed whether iPSC‐ECs form
functional microvasculature in a manner quantitatively and qualita-
tively similar to HUVECs in a well‐characterized three‐dimensional
fibrin‐based model of vasculogenesis in vivo. Both iPSC‐ECs and
HUVECs formed vessels with similar phenotypes and morphologies
and demonstrated some characteristics of vessel maturation. How-
ever, the iPSC‐ECs exhibited significantly reduced vessel density,
perfusion, and maturation in comparison with HUVECs.
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